Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug

MT Newswires Live06-16

Zai Lab (ZLAB) said Tuesday that the European Medicines Agency (EMA) has granted orphan drug designation to its experimental therapy, zocilurtatug pelitecan, for the treatment of pulmonary neuroendocrine carcinomas, a type of lung cancer.

The company said the designation follows a recommendation from the EMA's Committee for Orphan Medicinal Products, which cited preliminary clinical data suggesting that the therapy may offer a clinically meaningful advantage over currently approved treatments for relapsed or refractory extensive-stage small cell lung cancer, including the potential for durable responses.

Zai Lab said the orphan designation provides regulatory incentives that may support the therapy's development, including potential market exclusivity upon approval, reduced regulatory fees, and enhanced regulatory support.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment